DermTech Files for Voluntary Chapter 11 Protection
DermTech (NASDAQ: DMTK), a precision dermatology company, has filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. This move is part of the company's strategic alternatives review process. DermTech plans to continue laboratory operations and processing orders for its Melanoma Test while seeking to sell most of its assets. The company aims to protect stakeholders' interests and maximize asset value through the bankruptcy process. Advisors include Wilson, Sonsini, Goodrich & Rosati, PC, AlixPartners, and TD Cowen. Additionally, DermTech has implemented a reduction in force (RIF), resulting in the immediate layoff of approximately 15 employees, or 20% of its workforce, with possible future reductions.
- DermTech aims to continue its laboratory operations and processing orders.
- The company intends to maximize the value of its assets through the bankruptcy process.
- Advisors involved are reputable firms: Wilson, Sonsini, Goodrich & Rosati, AlixPartners, and TD Cowen.
- Filing for chapter 11 indicates financial distress.
- The company is looking to sell substantially all of its assets.
- An immediate reduction in force (RIF) resulted in laying off approximately 15 employees, or 20% of the workforce.
- There are potential additional reductions in the workforce.
Insights
DermTech's filing for voluntary Chapter 11 protection is a significant move, reflecting serious financial strain. This step usually indicates that a company is struggling to meet its debt obligations and seeks legal protection to reorganize and manage its liabilities. For retail investors, it's critical to understand that Chapter 11 allows the company to continue operations while restructuring its debts, which might offer some hope. However, the associated risks are high and the potential for equity holders to recover value is uncertain.
Key financial implications:
- The company’s intention to sell assets indicates a possible liquidation scenario, potentially leading to significant losses for shareholders.
- The reduction in force (RIF) highlights ongoing efforts to cut costs and preserve cash, which may be a necessary but painful measure.
- Advisors like AlixPartners and TD Cowen suggest that DermTech is seeking expert guidance to maximize asset value and navigate these turbulent times.
In short-term: Expect high volatility in DermTech's stock price. Long-term: Investors should be cautious. The outcome heavily depends on the restructuring process and asset sale success.
DermTech's focus on precision dermatology and non-invasive skin genomics technology positioned it as an innovative player in the healthcare sector. The Chapter 11 filing raises questions about the viability of their business model and market demand. While the company plans to continue operations and sell assets, its ability to maintain customer trust and market position is uncertain.
Key market implications:
- The strategic review process and asset sales may lead to potential acquisition interest from larger healthcare or biotech firms looking to capitalize on DermTech's technology.
- Market perception of the company’s stability can erode, impacting customer and investor sentiment.
- Competitors may seize this opportunity to strengthen their market position, potentially detracting from DermTech’s market share.
In short-term: Be prepared for an uncertain market reaction. Long-term: The company’s future hinges on the success of the restructuring and potential acquisition outcomes.
The Chapter 11 filing by DermTech involves legal intricacies that can significantly impact stakeholders. This legal process allows the company to reorganize under court supervision, providing a structured environment to address debts and operational challenges.
Key legal insights:
- Stakeholders, including creditors and shareholders, will need to closely monitor proceedings to understand their rights and possible recoveries.
- The involvement of experienced legal advisors like Wilson, Sonsini, Goodrich & Rosati, PC suggests the company aims to navigate this process efficiently and safeguard stakeholders’ interests.
- Bankruptcy court rulings will influence the outcome, including approval of any reorganization plans or asset sales.
In short-term: Legal proceedings will introduce uncertainty. Long-term: The resolution depends on the court's decisions and effectiveness of the reorganization plan.
DermTech is advised in this matter by Wilson, Sonsini, Goodrich & Rosati, PC, AlixPartners, Inc., and TD Cowen, a division of TD Securities.
Alongside the chapter 11 filings, the Company also implemented a reduction in force (RIF) to significantly reduce expenses associated with its current operations to preserve cash. This RIF resulted in an immediate workforce reduction of approximately 15 employees (approximately
About DermTech
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics technology. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected using its Smart StickersTM. DermTech develops and markets products that facilitate the assessment of melanoma. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “explore,” “estimate,” “project,” “budget,” “forecast,” ”aim,” “runway,” "outlook," “anticipate,” “intend,” “plan,” “strive," “may,” “will,” “sustain,” “remain," “continue,” “could,” “should,” “believe,” “predict,” “potential,” and similar expressions are intended to identify such forward‑looking statements. These forward-looking statements include, without limitation, expectations, evaluations and other statements with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products; expectations regarding DermTech’s financial outlook, including its cash runway, future financial performance and ability to reduce cost, expenses and cash burn, including as a result of DermTech’s restructuring plan; and the prospects for DermTech’s review and evaluation of potential strategic alternatives; and the terms, timing, structure, benefits and costs of any strategic transaction and whether one will be consummated at all; and statements regarding the chapter 11 proceeding. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional capital when and as needed or on acceptable terms or its ability to complete a strategic transaction, the failure of which may result in DermTech having to further curtail its operations, liquidate or otherwise dispose of assets, wind-down or cease operations entirely, any of which may result in stockholders receiving limited or no value for their investment; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by government payers (including Medicare) and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to manage its existing and potential future operations (including with respect to processing test orders), retain its key employees, maintain or improve its operating efficiency and reduce operating expenses, including, in each case, after the restructuring actions are complete; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; (9) the potential outcome and timing of DermTech’s announced process to explore strategic alternatives, including the potential that no such transaction will be completed in a timely manner or at all or that such a transaction will result in any value to stockholders; (10) DermTech’s ability to continue as a going concern, (11) DermTech’s ability to continue operating in the ordinary course while the chapter 11 proceeding is pending, and (12) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618662927/en/
Investor Relations
DermTech
investorrelations@dermtech.com
Source: DermTech, Inc.
FAQ
What did DermTech announce regarding chapter 11 protection?
Is DermTech continuing its operations after filing for chapter 11?
What is DermTech's plan during the bankruptcy process?
Which advisors are assisting DermTech in the bankruptcy process?
What workforce changes did DermTech announce along with the chapter 11 filing?
